PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.43%
R&D change of 15.43% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
12.93%
G&A change of 12.93% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
5.37%
Other expenses change of 5.37% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
14.34%
Operating expenses change of 14.34% versus flat Biotechnology costs. Walter Schloss would verify control.
14.34%
Total costs change of 14.34% versus flat Biotechnology costs. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
5.37%
D&A change of 5.37% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
-16.61%
EBITDA decline while Biotechnology median is -0.88%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-14.34%
Operating income decline while Biotechnology median is -1.23%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-295.23%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-20.40%
Pre-tax income decline while Biotechnology median is -3.91%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Net income decline while Biotechnology median is -4.20%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-19.61%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-20.61%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
0.76%
Share count reduction below 50% of Biotechnology median of 0.21%. Jim Chanos would check for issues.
No Data
No Data available this quarter, please select a different quarter.